Analyst Maintains Spec Buy on Biotech After Interim SAT-3247 DMD Data
Research Report

1.  This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., Satellos Bioscience Inc., March 10, 2026

Disclosures 2 Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO. Description of Disclosure Codes 1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives. 3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. Leede acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst. Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited. Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue. Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative. U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

In a research update published on March 10, 2026, Leede Financial analyst Douglas W. Loe, PhD, MBA, maintained a Speculative Buy rating and US$16.00 price target on Satellos Bioscience Inc. (MSCL:TSX; MSLE:NASDAQ), implying a 58% return from the current share price of US$10.10. The target is based on NPV using a 30% discount rate along with multiples of F2031 EBITDA and fully diluted EPS forecasts of US$81.0M and US$2.53 per share, respectively.

Satellos reported updated interim Phase II data from its 30-patient adult Duchenne muscular dystrophy TRAILHEAD trial, evaluating its orally-active AAK1 inhibitor SAT-3247. The update encompassed multiple efficacy endpoints, including biomarkers of disease, muscle function measurements, and a novel muscle regeneration analysis, all presented across three posters at the Muscular Dystrophy Association Clinical & Scientific Conference.

The analyst characterized the initial capital market response as somewhere between ambiguous and negative, noting that profit-taking likely played a role given the stock had appreciated 93% over the trailing six-month period. Loe described the clinical and biomarker data as more evolutionary than revolutionary in assessing SAT-3247's prospects.

On the biomarker front, data from five adult DMD patients in the completed Phase I safety/PK trial showed substantial and reproducible declines in DMD-associated serum biomarkers across a broad array of candidates, including CA3, ENO3, AK1, myoglobin, and ANKRD2. All five patients showed reductions in plasma levels of these markers by a similar magnitude, suggesting SAT-3247 may have a direct effect on muscle function through an AAK1-dependent pathway. Those five patients also experienced grip strength increases averaging between 98% and 119%.

The TRAILHEAD functional data from four evaluable patients were less conclusive. One patient appeared non-responsive to SAT-3247, showing no improvement in grip strength and experiencing declines in elbow and shoulder range of motion. The other three patients generally showed positive improvements, with strength and flexibility parameters apparently correlating with baseline creatinine levels, a surrogate for muscle mass. This finding suggests there may be a threshold of residual muscle function above which SAT-3247 is effective but below which it is not.

Satellos also introduced a proposed Regenerative Index (RI), measuring the ratio of muscle fibers with detectable embryonic myosin heavy chains to those with detectable immunoglobulin G, a marker of necrotic tissue. Loe noted the RI appears to correlate well with disease progression, showing lower values in older patients with more extensive muscle degeneration, and could serve as a prescreening tool to identify patients more likely to respond to SAT-3247.

The company's enterprise value calculation incorporates pro forma cash of US$88.1M, which includes FQ325 cash of US$34.6M plus net proceeds from the February 2026 equity offering, with no long-term debt and 23.3M fully diluted shares outstanding. Leede's financial model projects SAT-3247 royalty revenue beginning in F2030 at US$31.5M, growing to US$102.9M in F2031 and US$316.2M by F2035, with pivotal Phase III testing expected to conclude by the first half of 2029.

Key upcoming milestones include continued interim updates from both the TRAILHEAD adult trial and the newly initiated 51-patient BASECAMP pediatric DMD Phase II trial, which commenced enrollment in February 2026. Full BASECAMP enrollment is expected later in FQ226, with interim data at three-month follow-up expected over the coming months and final data during the first half of 2027.

Among comparable DMD-focused companies referenced in the report, notable peers include Sarepta Therapeutics Inc. (SRPT:NASDAQ) with a market cap of US$1.85B, Dyne Therapeutics Inc. (DYN:NASDAQ) at US$2.92B, Edgewise Therapeutics Inc. (EWTX:NASDAQ) at US$3.07B, and Capricor Therapeutics Inc. (CAPR:NASDAQ) at US$1.40B. Satellos trades at a market cap of approximately US$325M, substantially below the peer group averages.